Document is current
Any future updates will be listed below
-
Authors
Ramirez-Garcia, Teresa https://orcid.org/0009-0000-5207-1159
Cabezudo-Garcia, Pablo https://orcid.org/0000-0002-6421-5348
Garcia-Martin, Guillermina https://orcid.org/0000-0003-3894-9716
Lopez-Moreno, Yolanda
Sanchez-Guijo, Alvaro
De La Parra, Juan https://orcid.org/0000-0002-4443-8931
Serrano-Castro, Pedro J. https://orcid.org/0000-0002-3414-2707
-
Funding
Funding for this research was provided by:
Neuro-RECA (RIC-0111-2019)
Andalusia-Roche Alliance for Precision Medical Neurology
- License Information
-
More Information
Article History
Received: 15 September 2025
Accepted: 3 November 2025
First Online: 20 November 2025
Declarations
:
: Pedro J. Serrano-Castro has received consultant and/or speaker honoraria from Angelini Pharma, Bial, Eisai, Jazz Pharmaceuticals, Roche Pharmaceuticals, UCB Pharma, and Zogenix España. Pablo Cabezudo-Garcia has received consultant and/or speaker honoraria from Angelini Pharma, Bial, Eisai, Jazz Pharmaceuticals, UCB Pharma, Exeltis, and Neuraxpharm. Guillermina Garcia-Martin has received consultant and/or speaker honoraria from Bial, Eisai, Jazz Pharmaceuticals, and UCB Pharma. Juan De La Parra is a member of the Medical Department of Angelini Pharmaceuticals. Teresa Ramirez-Garcia, Yolanda Lopez-Moreno, and Alvaro Sanchez-Guijo have no disclosures.
: We confirm that we have read the Journal’s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines. The study protocol was approved by the Epilepsy Unit of Hospital Regional Universitario de Málaga's ethics committee and was in accordance with the code of ethics set out in the 1964 Declaration of Helsinki and its later amendments. For all patients participating in the Spanish EAP, written informed consent was obtained from the patient or their legal representative.
